A detailed history of Orbimed Advisors LLC transactions in Terns Pharmaceuticals, Inc. stock. As of the latest transaction made, Orbimed Advisors LLC holds 7,562,971 shares of TERN stock, worth $46.7 Million. This represents 1.49% of its overall portfolio holdings.

Number of Shares
7,562,971
Previous 7,619,135 0.74%
Holding current value
$46.7 Million
Previous $51.9 Million 21.56%
% of portfolio
1.49%
Previous 1.25%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 14, 2024

SELL
$6.49 - $10.8 $364,504 - $606,571
-56,164 Reduced 0.74%
7,562,971 $63.1 Million
Q4 2022

Feb 14, 2023

BUY
$4.62 - $10.18 $637,241 - $1.4 Million
137,931 Added 1.84%
7,619,135 $77.6 Million
Q3 2022

Nov 14, 2022

BUY
$1.87 - $6.42 $6.9 Million - $23.7 Million
3,690,000 Added 97.33%
7,481,204 $44.1 Million
Q1 2021

May 17, 2021

BUY
$17.13 - $27.25 $64.9 Million - $103 Million
3,791,204 New
3,791,204 $83.4 Million

Others Institutions Holding TERN

About Terns Pharmaceuticals, Inc.


  • Ticker TERN
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 37,613,800
  • Market Cap $232M
  • Description
  • Terns Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis (NASH) and obesity. The company develops TERN-101, a liver-distributed and non-bile acid farnesoid X receptor agonist, which is in Phase IIa clinical t...
More about TERN
Track This Portfolio

Track Orbimed Advisors LLC Portfolio

Follow Orbimed Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Orbimed Advisors LLC with notifications on news.